Article
Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
The oncologist - 1 Jun 2009
Gridelli Cesare, Maione Paolo, Ferrara Marianna Luciana, Rossi Antonio
Abstract excerpt
Non-small cell lung cancer (NSCLC) accounts for about 85% of all new diagnoses of lung cancer. Unfortunately, few NSCLC patients are suitable for radical treatment for curative intent. Because most patients with NSCLC have advanced disease at diagnosis, chemotherapy represents the standard of care, although, to date, a plateau has been reached with this approach. Improvements in the knowledge of tumor biology and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.